gastrointestinal stromal tumour (GIST)
Oncology · 2011–2015
4decisions
2medicines
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| regorafenib Treatment of metastatic or unresectable gastrointestinal stromal tumours (GIST) after failure of or intolerance to imatinib mesylate and sunitinib. | Mar 2015 | Not recommended | 1 individuals |
| imatinib Adjuvant treatment of patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Mar 2012 | Not recommended | no section in document |
| imatinib Adjuvant treatment of patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST). | Nov 2012 | Recommended with restriction | no section in document |
| imatinib Adjuvant treatment of adult patients at high risk of recurrence following complete resection of primary gastrointestinal stromal tumour (GIST) with… | Mar 2011 | Recommended with restriction | no section in document |
What the PBS pays
$9M in government benefit over 2024–25, across 29,917 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| imatinib | $8.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.